Prana Biosciences
PraNa Biosciences is a Massachusetts-based biotherapeutics company focused on discovery, development, and commercialization of improved follow-on antibody therapies (biobetters). The company emphasizes monoclonal antibody engineering, intracellular delivery approaches, and scalable biologics production with an on‑shore operational model. Leadership experience reported includes drug discovery, biologics CMC, GMP manufacturing, regulatory filings with health authorities, and IP/patenting.
Industries
Nr. of Employees
small (1-50)
Prana Biosciences
Worcester, Massachusetts, United States, North America
Patents
Products
Discovery platform for novel therapeutics
Platform for target selection and generation of novel therapeutic candidates using nature‑informed and scientific discovery approaches.
Development platform for intracellular delivery and optimization
Platform combining therapeutic structure/function development and cell‑specific internal delivery of cargo to restore intracellular homeostasis.
Manufacturing platform for protein therapeutics
Platform focused on robust and affordable production of protein therapeutics, including process development and scaled production partnerships.
Pipeline overview
Visual pipeline and value‑creation strategy for advancing antibody biobetters from discovery through commercialization (images shown on the website).
Facility tour and imagery
Multimedia facility tour and images showing laboratory spaces and R&D facilities.
Best‑in‑class antibody (BiCAB) platform
Integrated platform to design, develop, and produce improved monoclonal antibodies with emphasis on functional differentiation and manufacturability.
Discovery platform for novel therapeutics
Platform for target selection and generation of novel therapeutic candidates using nature‑informed and scientific discovery approaches.
Development platform for intracellular delivery and optimization
Platform combining therapeutic structure/function development and cell‑specific internal delivery of cargo to restore intracellular homeostasis.
Manufacturing platform for protein therapeutics
Platform focused on robust and affordable production of protein therapeutics, including process development and scaled production partnerships.
Pipeline overview
Visual pipeline and value‑creation strategy for advancing antibody biobetters from discovery through commercialization (images shown on the website).
Facility tour and imagery
Multimedia facility tour and images showing laboratory spaces and R&D facilities.
Best‑in‑class antibody (BiCAB) platform
Integrated platform to design, develop, and produce improved monoclonal antibodies with emphasis on functional differentiation and manufacturability.
Services
Target identification, antibody redesign and optimization to improve function and manufacturability for therapeutic development.
Design and run binding and functional assays (ELISA, Western blot, IF/IHC, cell‑based functional assays) to characterize candidate biologics.
Support for master cell bank creation, process development and small‑to‑mid scale GMP production through internal capabilities and manufacturing partnerships.
Company platforms and pipeline focus areas (discovery, development, and manufacturing platforms for antibody biobetters and intracellular delivery modalities).
Discovery platform for target identification and novel therapeutic generation; development platform for intracellular delivery and therapeutic optimization; manufacturing platform for scalable protein therapeutic production.
Development of improved follow‑on antibody therapeutics aimed at safety/efficacy differentiation and broader patient access.
Target identification, antibody redesign and optimization to improve function and manufacturability for therapeutic development.
Design and run binding and functional assays (ELISA, Western blot, IF/IHC, cell‑based functional assays) to characterize candidate biologics.
Support for master cell bank creation, process development and small‑to‑mid scale GMP production through internal capabilities and manufacturing partnerships.
Company platforms and pipeline focus areas (discovery, development, and manufacturing platforms for antibody biobetters and intracellular delivery modalities).
Discovery platform for target identification and novel therapeutic generation; development platform for intracellular delivery and therapeutic optimization; manufacturing platform for scalable protein therapeutic production.
Development of improved follow‑on antibody therapeutics aimed at safety/efficacy differentiation and broader patient access.
Expertise Areas
- Antibody therapeutics development
- Biobetter design and optimization
- Biologics CMC and process development
- Assay development and analytical characterization
Key Technologies
- Monoclonal antibody engineering
- Intracellular delivery platforms
- Cell‑based functional assays
- ELISA and immunoblotting